TY - JOUR
T1 - Long-term outcomes of different ablation strategies for ventricular tachycardia in patients with structural heart disease
T2 - Systematic review and meta-analysis
AU - Bricenõ, David F.
AU - Romero, Jorge
AU - Villablanca, Pedro A.
AU - Londonõ, Alejandra
AU - Diaz, Juan C.
AU - Maraj, Ilir
AU - Batul, Syeda Atiqa
AU - Madan, Nidhi
AU - Patel, Jignesh
AU - Jagannath, Anand
AU - Mohanty, Sanghamitra
AU - Mohanty, Prasant
AU - Gianni, Carola
AU - Della Rocca, Domenico
AU - Sabri, Ahlam
AU - Kim, Soo G.
AU - Natale, Andrea
AU - Di Biase, Luigi
PY - 2018/1/1
Y1 - 2018/1/1
N2 - To compare the long-term outcomes of standard ablation of stable ventricular tachycardia (VT) vs. substrate modification, and of complete vs. Incomplete substrate modification in patients with structural heart disease (SHD) presenting with VT. Methods and results An electronic search was performed using major databases. The main outcomes were a composite of long-term ventricular arrhythmia (VA) recurrence and all-cause mortality of standard ablation of stable VT vs. substrate modification, and long-term VA recurrence in complete vs. Incomplete substrate modification. Six studies were included for the comparison of standard ablation of stable VT vs. substrate modification, with a total of 396 patients (mean age 63 ± 10 years, 87% males), and seven studies were included to assess the impact of extensive substrate modification, with a total of 391 patients (mean age 64 ± years, 90% males). More than 70% of all the patients included had ischaemic cardiomyopathy. Substrate modification was associated with decreased composite VA recurrence/all-cause mortality compared to standard ablation of stable VTs [risk ratio (RR) 0.57, 95% confidence interval (CI) 0.40-0.81]. Complete substrate modification was associated with decreased VA recurrence as compared to incomplete substrate modification (RR 0.39, 95% CI 0.27-0.58). Conclusion In patients with SHD who had VT related mainly to ischaemic substrates, there was a significantly lower risk of the composite primary outcome of long-term VA recurrence and all-cause mortality among those undergoing substrate modification compared to standard ablation. Long-term success is improved when performing complete substrate modification.
AB - To compare the long-term outcomes of standard ablation of stable ventricular tachycardia (VT) vs. substrate modification, and of complete vs. Incomplete substrate modification in patients with structural heart disease (SHD) presenting with VT. Methods and results An electronic search was performed using major databases. The main outcomes were a composite of long-term ventricular arrhythmia (VA) recurrence and all-cause mortality of standard ablation of stable VT vs. substrate modification, and long-term VA recurrence in complete vs. Incomplete substrate modification. Six studies were included for the comparison of standard ablation of stable VT vs. substrate modification, with a total of 396 patients (mean age 63 ± 10 years, 87% males), and seven studies were included to assess the impact of extensive substrate modification, with a total of 391 patients (mean age 64 ± years, 90% males). More than 70% of all the patients included had ischaemic cardiomyopathy. Substrate modification was associated with decreased composite VA recurrence/all-cause mortality compared to standard ablation of stable VTs [risk ratio (RR) 0.57, 95% confidence interval (CI) 0.40-0.81]. Complete substrate modification was associated with decreased VA recurrence as compared to incomplete substrate modification (RR 0.39, 95% CI 0.27-0.58). Conclusion In patients with SHD who had VT related mainly to ischaemic substrates, there was a significantly lower risk of the composite primary outcome of long-term VA recurrence and all-cause mortality among those undergoing substrate modification compared to standard ablation. Long-term success is improved when performing complete substrate modification.
UR - http://www.scopus.com/inward/record.url?scp=85040771382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040771382&partnerID=8YFLogxK
U2 - 10.1093/europace/eux109
DO - 10.1093/europace/eux109
M3 - Review article
C2 - 28575378
AN - SCOPUS:85040771382
SN - 1099-5129
VL - 20
SP - 104
EP - 115
JO - Europace
JF - Europace
IS - 1
ER -